Diasorin SpA (WBO:DIAS) Other Operating Expense: €189 Mil (TTM As of Dec. 2025)


WBO:DIAS Diasorin SpA WBO:DIAS
74 GF Score
Price €70.08
GF Value €90.10
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA Other Operating Expense?

Diasorin SpA WBO:DIAS +0.43% 74 Other Operating Expense is €189 Mil as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.10 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Diasorin SpA's Other Operating Expense for the three months ended in Dec. 2025 was €37 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €189 Mil.

Diasorin SpA's quarterly Other Operating Expense declined from Jun. 2025 (€22 Mil) to Sep. 2025 (€2 Mil) but then increased from Sep. 2025 (€2 Mil) to Dec. 2025 (€37 Mil).

Diasorin SpA's annual Other Operating Expense increased from Dec. 2023 (€44 Mil) to Dec. 2024 (€49 Mil) but then declined from Dec. 2024 (€49 Mil) to Dec. 2025 (€45 Mil).

Diasorin SpA Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Other Operating Expense Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.94 63.60 44.26 48.95 44.73

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 22.50 2.00 36.73 128.00
WBO:DIAS
74GF Score
Diasorin SpA WBO:DIAS
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €189 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €189 Mil mean?
Diasorin SpA (WBO:DIAS) has a Other Operating Expense of €189 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Other Operating Expense too high?
Diasorin SpA's current Other Operating Expense is €189 Mil. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Other Operating Expense compare to TMO and DHR?
Diasorin SpA's Other Operating Expense of €189 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Diagnostics & Research company?
A good Other Operating Expense depends on the Medical Diagnostics & Research industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Other Operating Expense is €189 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.10, compared to a current price of €70.08 — trading 22.2% below its estimated fair value. The current Other Operating Expense is €189 Mil. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Other Operating Expense is €189 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €70.08 is trading 22.2% below its estimated GF Value™ of €90.10. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for WBO:DIAS:

  • Other Operating Expense: €189 Mil
  • GF Value™: €90.10 vs. price of €70.08 (22.2% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score

Get the complete analysis for WBO:DIAS

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.08
Price
€90.10
GF Value